烟台市市直机关工作人员心血管病危险因素调查分析

目的了解机关工作人员心血管病危险因素的发病情况、年龄特点及10年的变化等.方法在1993年和2002年前后两次对烟台市市直机关2000余名工作人员进行健康体检,并进行对比.结果 2002年心血管病的主要危险因素高脂血症、高血压、高血糖的发生率分别为20.30%、9.76%和2.85%,与1993年(15.15%、4.24%和1.84%)相比显著增高(P＜0.01、P＜0.01、P＜0.05),且两次比较有明显年轻化改变.同时对心血管病危险因素再次得以验证.结论心血管病危险因素的发病率较10年前明显增高,采取综合防治措施是控制和降低机关工作人员心血管病危险因素患病率之当务之急.     

Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients

Abstract

An open-label follow-up study of low-to-intermediate dose testosterone replacement therapy (TRT) was conducted in 64 overweight patients (aged 65–75 years) with late onset hypogonadism (LOH) and increased fasting plasma glucose (FPG). Patients were subdivided into four treatment groups: oral testosterone (T) (T undecanoate, 80?mg/d), transmucosal T (60?mg/d), transdermal T (30?mg/d) or no treatment (control), and evaluated at 0 and 6 months. FPG, hemoglobin (Hb), prostate-specific antigen (PSA) and total T were measured and the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index was calculated. Body mass index (BMI), waist circumference, fitness level (6-min walking test), Aging Males’ Symptoms (AMS) scale, handgrip strength and energy expenditure with physical activity (Minnesota questionnaire for Leisure Time Physical Activity (LTPA)) were evaluated and a “frailty score” (based on: grip strength, gait speed and LTPA) was calculated. T levels increased in all treatment groups; the oral T group had values still in the hypogonadal range (5.9?±?1.1?nmol/L). PSA and Hb concentrations did not change in any group. BMI, waist circumference, FPG and HOMA-IR improved in all T-treated groups after 6 months, with a greater effect seen with transmucosal and transdermal T compared with oral T. This study indicates that low-to-intermediate dose TRT may be safely utilized in LOH patients to ameliorate somatic and psychological frailty symptoms in association with improved anthropometric and glycometabolic parameters in aging, overweight men with LOH and impaired fasting glucose.